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Ventricular Arrhythmias in Congenital Heart Disease
JEFFREY P. MOAK , MD, FACC , RICHARD T. SMITH, MD, FACe,
ARTHUR GARSON, JR., MD, FACC
Houston, Texas
The use of antiarrhythmic drugs to suppress ventricular
arrhythmias in pediatric patients with a structurally or
hemodynamically abnormal heart appears to improve
long-term prognosis. The previously successful use of
phenytoin to treat serious ventricular arrhythmias led
to the investigation for an alternative antiarrhythmic
agent, in the same antiarrhythmic drug class, for those
patients who develop side effects or become intolerant
to phen ytoin 's antiarrhythmic effect. Forty-two children
and young adults (age range 5 months to 34 yea rs, mean
15.5 years) were treated with mexiletine. Arrhythmias
treated were ventricular tachycardia (25), ventricular
couplets (8), multiform ventricular premature beats (4)
and frequent uniform ventricular premature beats (5 ).
Anatomic diagnoses included congenital heart disease
(postoperative in 26, unoperated in 2), cardiomyopathy
(7), no heart disease (4) and other (3). Thirty-three pa-
tients had been pre viously treated with 1 to 5 (mean 1.6)
antiarrhythmic drugs.
The succe ssful control of ventricular arrhythmias has proved
efficacious in decreasing the morbidity and mortality amon g
children with heart disease (I). Howe ver, drug treatment of
ventricular arrhythmias with many of the currently avai lable
antiarrhythmic agents may be complicated by impairment
of myocardial function and side effects (2) .
Many pediatric patients with ventricular arrhythmias have
complicated congenital heart disease associated with myo-
cardial dysfunct ion . Phenytoin has been previously dem-
onstrated to be highly effective in the treatment of serious
ventricular arrhythmias in patients with congenital heart dis-
ease and to cause few side effects (3 ,4). However, alter-
native antiarrhythmic therapy is needed for those patients
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In the short term, ventricular arrhythmias were ef-
fectively suppressed in 30 (71%) of all 42 patients treated.
During follow-up (ranging to 42 months, median 10.6),
18 (60% ) of the 30 acute responders continued to have
excellent control. Early suppression of ventricular ar-
rhythmias was more effective in patients with congenital
heart disease (89% ) than in those with cardiomyopathy
(29%) or no heart disease (43%) (p < 0.01). Initial com-
plexity of ventr icular ectopic activity had no effect on
treatment results.
Of 25 patients previously treated with phenytoin, in
whom alternative antiarrhythmic therapy was required ,
40% had long-term arrhythmia control when treated
with mexiletine. Mexiletine therapy was terminated for
side effects in only five patients (12%). Mexiletine is
recommended for young patients with congenital heart
disease and serious ventricular arrhythmias.
(J Am Coil Cardiol /987;10:824-9)
who develop phenytoin-induced side effects (rash or gin-
gival hyperplasia) and young female patients desir ing to
becom e pregnant , in whom other antiarrhythmic drugs have
been ineffective . Because phenytoin has been so effective ,
we sought to study an alternative antiarrhythmic drug. rnex-
iletine , which has similar electrophysiologic properties (type
Ib local anesthetic effect) . Furthermore , mexiletine has been
shown to be effec tive in the treatment of adult patients with
ventricular arrhythmias and ischemic heart disease. But more
important , there has been little evidence of impairment of
myocardial function or only rare instances of arrhythmia
aggravation secondary to its use (5-8). Thi s report rev iews
the effec tiveness and toxici ty of mexiletine in treating se-
rious ventricular arrhythmias in infants, children and young
adults.
Methods
Study patients. The study group co mprised 42 patients
with clinically significant ventricular ectopic activity . Ven-
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tricular arrhythmias treated included isolated ventricular
premature beats (uniform or multiform) with a frequency
> 30/h, ventricular couplets or ventricular tachycardia. Ven-
tricular tachycardia was defined as the occurrence of three
or more consecutive excitations originating from the ven-
tricle at a rate 2: 120/min. Patients older than 18 years were
included if they had congenital heart disease.
Mexiletine protocol. Each patient was admitted to the
hospital for mexiletine treatment. All antiarrhythmic drugs,
except digoxin, were discontinued 5 drug half-lives before
commencing mexiletine therapy. Pretreatment laboratory
work-up included: 15 lead electrocardiogram (ECG); con-
tinuous ambulatory electrocardiogram usually starting 36 to
48 hours before initiating therapy; chest X ray film; echo-
cardiogram; treadmill test; complete blood count with dif-
ferential and platelet count; blood urea nitrogen and creat-
inine determinations; and liver function tests.
After these baseline studies were obtained, oral mexi-
letine was initiated with a dose of 2.9 mg/kg every 8 hours.
Seventy-two hours were allowed for a steady state to be
reached. Although this time period exceeded 5 drug half-
lives calculated using the average adult drug half-life of
12.1 hours (9), we chose it to ensure that a true steady state
had been achieved. At this point, blood was drawn for
determination of the serum concentration (trough level) and
the continuous ECG was analyzed for effectiveness. If the
drug was ineffective (see later) and there were no side ef-
fects, the dose of mexiletine was increased to 4.3 mg/kg
every 8 hours and 72 hours were allowed to elapse at which
point effectiveness was redetermined. At no time did any
patient receive more than 5.0 mg/kg per dose. If at any dose
mexiletine was effective but caused significant side effects,
Table l. Anatomic Diagnosis in 42 Patients
the dosage was decreased by one-half and effectiveness was
reevaluated.
Routine outpatient follow-up was scheduled at I, 3 and
6 months and I year and then every 6 months after the start
of treatment with mexiletine. Outpatient data included his-
tory, physical examination, IS lead ECG, chest X ray film,
24 hour ambulatory ECG and repetition of all initial labo-
ratory blood tests.
Criteria for drug efficacy. Mexiletine effecti veness was
assessed on the basis of continuous electrocardiography.
Treatment was considered successful for patients being treated
for ventricular couplets or ventricular tachycardia (three or
more consecutive ventricular premature beats) if there was
complete elimination of the arrhythmia. In patients being
treated for frequent uniform or multiform ventricular pre-
mature beats (frequency >30/h), therapy was considered
successful if there was an 85% reduction in the number of
ventricular premature beats during a 24 hour period (10, II).
In patients in whom ventricular tachycardia or couplets
could be provoked during exercise, mexiletine was consid-
ered successful if on repeated treadmill exercise tests mex-
iletine prevented the reappearance of ventricular tachycardia
or couplets.
Blood level assay. Mexiletine serum concentrations were
determined by high pressure liquid chromatography by
Boehringer Ingelheim, Ltd. A therapeutic concentration of
mexiletine has been suggested to range between 0.5 and 2.0
mg/liter (9)
Statistical analysis. Analysis of variance (ANOV A) was
performed for multigroup comparisons. If the ANOVA was
statistically significant (p < 0.05), Bonferroni's modifica-
tion of the l test was subsequently used for pairwise com-
parisons (12). Statistical significance was inferred if the
probability of a difference occurring by chance was <0.05.
Congenital heart disease
Tetralogy of Fallot/pulmonary atresia +
ventricular septal defect
Aortic stenosis
Ventricular septal defect + pulmonary vascular
obstructive disease
Truncus arteriosus
AV canal defect
D-transposition of great arteries + ventricular
septal defect
Ltransposition of great arteries + ventricular
septal defect + pulmonary stenosis
Tricuspid atresia
Cardiomyopathy
Purkinje cell tumor
Status post AV node ablation
No heart disease
AV = atrioventricular.
No. of
Patients
12
4
4
2
2
2
[
7
2
I
4
Results
Clinical Features
Cardiac diagnoses (Table 1). All except 4 of the 42
patients enrolled in the study had an abnormal heart. The
most common cardiac diagnosis was congenital heart dis-
ease, which was reported in 28 patients (67%). Of these 28
patients, 26 had had previous cardiac surgery and 2 had had
no operation. The next most common cardiac condition
treated was cardiomyopathy (in seven patients, three of whom
had arrhythmogenic right ventricular dysplasia). Two pa-
tients had Purkinje cell tumors. One patient had previously
undergone atrioventricular (A V) node ablation for incessant
supraventricular tachycardia and had an associated dilated
cardiomyopathy.
Age of onset, duration of therapy and dose. The pa-
tients ranged in age from 5 months to 34 years (mean 15.5
years) when mexiletine therapy was instituted. The duration
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of therapy has ranged up to 42 months (mean 10.6). Seventy
percent of patients in whom mexiletine was continued be-
yond the early drug testing stage had follow-up > 6 months.
The dose of mexiletine utilized ranged from 1.4 to 5.0 mg/kg
(mean 3.3) every 8 hours.
Ventricular arrhythmias. All patients had frequent
ventricular ectopic activity documented by ECG monitoring.
Twenty-five patients had recurrent episodes of ventricular
tachycardia, eight had ventricular couplets, four had mul-
tiform ventricular premature beats and five had uniform
ventricular premature beats. Six patients had sustained, in-
cessant ventricular tachycardia. The 19 patients with non-
sustained ventricular tachycardia had a mean of 6.8 ± 3,7
beats/run and 70.9 ± 219.9 runs of ventricular tachycar-
dia/24 h. Ventricular couplet frequency ranged from 2 to
48/24 h (mean 9.6 ± 16.5). The frequency of isolated
uniform or multiformed ventricular premature beats was
> 30/h.
Previous therapy (Table 2). Thirty-three patients had
been previously treated with I to 5 (mean 1.6) antiarrhyth-
mic drugs. Phenytoin had been used in 25 patients (60%).
All previous antiarrhythmic drugs were discontinued be-
cause of inadequate arrhythmia control or side effects.
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Table 2. Previous Antiarrhythmic Therapy in 42 Patients
Mexilet ine Therapy
Effectiveness: overall. Shortly after the start of mexi-
letine therapy, ventricular arrhythmias were effectively sup-
pressed in 30 (71%) of the 42 patients. Therapy was ter-
minated early in the other 12 patients because of inadequate
arrhythmia control. During follow-up, 18 (60%) of the 30
patients who continued on mexiletine treatment had excel-
lent control of their arrhythmia. Mexiletine was discontin-
ued in five patients because of side effects and in seven
(23%) because of late arrhythmia recurrence.
Effectiveness: heart disease. Mexiletine was most ef-
fective in suppressing ventricular arrhythmias in patients
with congenital heart disease (Fig. I). In the 28 patients
with congenital heart disease, complete arrhythmia control
was achieved in 25 (89%) early after initiation of therapy.
Fourteen (56%) of these 25 patients continued to have sue-
Phenytoin
Propranolol
Quin id ine
Atenolol
Procainamide
Disopyram ide
Verapamil
Amiodarone
Flecainide
No. of
Patients
25
8
6
3
2
2
2
2
I
Figure1. Arrhythmiacontrol and typeofassociated heart disease.
The analysis was performed by evaluating the percent of patients
with specific types of heart disease who had effective control of
arrhythmia early during therapy: all patients (overall) (n = 42),
those with congenital heartdisease (CHD), cardiomyopathy (CM)
and no heart disease (NHD). Mexiletine therapy wasmosteffective
in the group with congenital heart disease (*p < 0.0 I ).
cessful control of their arrhythmia during follow-up. Mex-
iletine was discontinued in four (16%) for drug-related side
effects and in seven (28%) because of arrhythmia recurrence
late after initiationof therapy. In the cardiomyopathy group
(seven patients), mexiletine therapy was moderately effec-
tive, but less so than in the group with congenital heart
disease. Long-term arrhythmia control occurted in two (29%)
of the seven patients. The. no heart disease group (four
patients) and the two miscellaneous groups of Purkinje cell
tumor (two patients) and AV node ablation (one patient)
were analyzed collectively. Successful long-term arrhyth-
mia suppression occurred in two (29%) of these seven pa-
tients; one had a Purkinje cell tumor and the other had had
AV node ablation. Mexiletinc therapy was least effective
in the patient groups of cardiomyopathy and no heart dis-
ease.
Effectiveness: arrhythmia type. No significant di f fer-
ences were evident between the presenting arrhythmia type
and the adequacy of long-term arrhythmia control (Fig. 2).
Continued effective arrhythmia control was maintained in
12 (48%) of 25 patients with ventricular tachycardia, 3
(43%) of 7 patients with ventricular couplets and 3 (33%)
lACC Vol. 10, No.4
October 1987:824--9
MOAK ET AL.
TREATMENT OF VENTRICULAR ARRHYTHMIAS
827
Figure 2. Arrhythmia control and complexity of ventricular ar-
rhythmia. The analysis was performed by evaluating the percent
of patients with specific grades of ventricular ectopic activity (fre-
quent isolated ventricular premature beats [VPB's], couplets and
ventricular tachycardia [VT]) who had effective long-term ar-
rhythmia control. Mexiletine's efficacy was not significantly in-
fluenced by the complexity of the ventricular ectopic activity that
was treated.'J .
of 9 patjpnts with either isolated frequent multiform or uni-
form ventricular premature beats.
Effectiveness: previous phenytoin failures. Of the 25
patients previously treated with phenytoin, therapy had been
terminated because of inadequate arrhythmia control in 12.
rash in 12 and gingival hyperplasia in I patient. Twenty-
one (84%) of these patients had excellent arrhythmia control
during the early phases of mexiletine therapy. Completely
successful long-term arrhythmia control was achieved in 10
(48%) of these 2I patients. Mexiletine was stopped because
of side effects in four and arrhythmia recurrence in seven
patients.
Concomitant therapy. Mexiletine was used in combi-
nation with another antiarrhythmicagent in six patients. This
included a beta-receptor blocker in four patients. procain-
amide in one and phenytoin in one. Concomitant phenytoin
and mexiletine therapy was used in one patient who had
fair arrhythmia control with phenytoin alone. Higher doses
of phenytoin had produced central nervous system side ef-
fects. Phenytoin treatment was supplemented with mexi-
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!etine in the hope of improving arrhythmia control without
causing significant side effects. Unfortunately, the combi-
nation produced little improvement in arrhythmia control.
The concomitant use of additional antiarrhythmic agents in
patients with fair arrhythmia control with mexiletine rarely
enhanced therapeuticeffectiveness. Only two (33%)ofthese
six patients had long-term suppression of their arrhythmia.
Adverse effects. The incidence and type of side effects
noted during therapy with mexiletine are listed in Table 3.
Twenty-eight (67%) of the 42 patients had no side effects.
The remaining 14 patients had side effects, but most of
these were well tolerated and usually disappeared with a
decrease in the dosage of mexiletine. Mexiletine was dis-
continued because of side effects in only five (12%) of the
enrolled patients. The most common side effect, nausea,
occurred in II patients. Administration of mexiletine with
food usually abated this symptom. Nine patients had symp-
toms referable to the central nervous system. Headaches
occurred in six; tremor and mood changes in three; vertigo
in two; and paresthesias in one patient. A morbilliform rash
erupted during mexi!etine therapy in two patients. One pa-
tient with moderately impaired renal function (creatinine
clearance not measured) experienced hypotension and sinus
tachycardia after the first several doses of mexiletine. The
hypotension resolved with cessation of therapy. Of partic-
ular importance was the fact that there was no exacerbation
of congestive heart failure in any of the patients treated or
an increase in the quantity of their ventricular ectopic ac-
tivity.
The measured serum concentrations ofmexiletine ranged
from0.3 to I .9 mg/liter. Nocorrelation was evident between
therapeutic effectiveness or side effects and serum concen-
tration of mexiletine. The serum concentration of patients
with side effects was frequently in the "therapeutic range."
Similarly. no relation between serum concentration and drug
response could be demonstrated.
Table 3. Long-Term Mexiletine Side Effects in 14 Patients
No. of
Side Effect Patients
Gastrointestinal II
Nausea II
Neurologic 9
Headache 6
Tremor 3
Mood changes 3
Vertigo 2
Paresthesias I
Dermatologic 2
Rash 2
Cardiovascular
Hypotension
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Discussion
Mexiletine effectiveness. The results of this study dem-
onstrate mexiletine to be· highly effective in treating ven-
tricular arrhythmias in children and young adults. After
initiating therapy with mexiletine, 71% of all patients achieved
early arrhythmia suppression as documented by continuous
ECG monitoring. Early arrhythmia control was particularly
high in the subgroup of patients with congenital heart disease
(89%). Mexiletine effectively suppressed all grades of ven-
tricular ectopic activity equally well.
Comparison with other antiarrhythmic drugs. In-
creasing awareness of the importance of ventricular arrhyth-
mia control in pediatric patients with an abnormal heart
(structural heart disease or cardiomyopathy) naturally brings
to the foreground questions concerning antiarrhythmic drug
efficacy (1,13). Few reports are available from which a
comparative analysis of antiarrhythmic efficacy can be made
(14). Most reported series contain small numbers of treated
patients. Furthermore, the spectrum of antiarrhythmic drugs
studied is limited. However, the largest antiarrhythmic ex-
perience reported to date has been with either phenytoin or
amiodarone (3,4,15-18).
Previous investigators have noted favorable results with
these agents (3,4,15-18). In using phenytoin to treat 51
patients with chronic ventricular arrhythmias, Garson and
Gillette (3) observed successful arrhythmia control early
after initiating therapy in 76% of patients. Satisfactory ar-
rhythmia control was maintained in 57% of patients during
a mean follow-up period of 15.2 months. The experience
of Kavey et al. (4) in treating 19 patients with phenytoin
was similar; 74% had effective arrhythmia control early
during therapy. A favorable experience with amiodarone
was noted by a number of investigators. In the two largest
series reported (15,16), the observed early success rate was
high, ranging from 70 to 86%; long-term success was achieved
in 54% of patients on amiodarone therapy followed up by
Garson et al. (16).
Our results with mexiletine compared quite favorably
with the results using these two other agents. Earlyarrhyth-
mia control occurred in 71% of all patients initially treated
with mexiletine (89% of those with congenital heart dis-
ease); during long-term follow-up, arrhythmia control was
maintained in 50% of patients with congenital heart disease.
Twenty-five of our patients had previously been treated
with phenytoin. Excellent early arrhythmia control occurred
in 84% of this subgroup, whereas 40% had effective long-
term control. For those patients in whom phenytoin therapy
must be discontinued because of side effects (rash, gingival
hyperplasia or hirsutism), we recommend treatment with
mexiletine. Because of phenytoin's known teratogenicity
(19), one additional subgroup of patients in whom alter-
native antiarrhythmic therapy should be considered is young
women desiring to become pregnant. To date, no reports
have attributed a teratogenic effect to mexiletine.
Antiarrhythmic therapy-which agent to use? Before
choosing an antiarrhythmic agent for a particular patient,
consideration should be given to the type of underlying heart
disease. Evidence is becoming available to suggest the im-
portant influence the type of underlying heart disease has
in modifying the response to treatment. Ventricular arrhyth-
mias in patients with congenital heart disease appear par-
ticularly sensitive to phenytoin and mexiletine (1,3,4). In
the present study evaluating mexiletine and in a previous
report (3) using phenytoin, arrhythmia control was best
achieved in patients with congenital heart disease. Patients
with congestive cardiomyopathy and subjects with no heart
disease responded less well to therapy with these two agents.
Although not advocating treatment of ventricular arrhyth-
mias in children with no heart disease, we recognize its
necessity in symptomatic patients and those with secondary
impairment of cardiac function. Propranolol and quinidine
have been reported to be efficacious in patients without heart
disease (14,18,20). However, these two agents are thera-
peutically less effective than mexiletine or phenytoin in
patients with congenital heart disease (I).
In deciding on an antiarrhythmic agent for patients with
diminished cardiac function, serious thought should be given
to its negative inotropic effects. The reported experience
with mexiletine usage in adult patients with ischemic heart
disease has been quite favorable (5-8). A review of studies
by Shanks (21) found mexiletine nearly devoid of adverse
hemodynamic effects when administered in a dosage that
maintained "therapeutic" plasma concentrations. No ex-
acerbation of congestive heart failure occurred in our pa-
tients. Hypotension developed in one patient who had renal
failure. Marked impairment of renal function is known to
diminish the clearance of mexiletine (9) and probably con-
tributed to its accumulation in this patient, although a serum
concentration was not available. Several local anesthetic
agents, particularly disopyramide, quinidine and procain-
amide, have significant negative inotropic effects and should
be avoided in patients with compromised cardiac function
(2).
A frequently reported complication of local anesthetic
antiarrhythmic drug usage is arrhythmia aggravation. Re-
peated documentation of this complication can be found in
reports of patients with ischemic heart disease treated with
local anesthetic agents (22,23). It has been reported (20,25)
in the pediatric age group during quinidine administration.
The true incidence of this side effect, however, is unknown.
The reported incidence of proarrhythmic effects has been
significantly lower with mexiletine treatment (5-8). In our
series, we did not observe any exacerbation of ventricular
arrhythmias.
Therapeutic effectiveness in pediatric patients: prob-
able role of the underlying heart disease. Our results and
those of previous studies (3,4) demonstrate that mexiletine
and phenytoin have an enhanced therapeutic effectiveness
in treating pediatric and young adult patients with congenital
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heart disease, in contrast to the reported low effectiveness
of these agents in adult patients with ischemic heart disease
(5-8). Speculation regarding the basis for enhanced thera-
peutic effectiveness of phenytoin and mexiletine (type lb
local anesthetic agents) in pediatric and young adult patients
may be directed toward either the patients' younger age or
a difference in electrophysiologic substrate for the ventric-
ular arrhythmias (congenital heart disease versus ischemic
heart disease). We favor the latter hypothesis. Many of our
patients (36%) were teenagers or young adults. In addition,
recent studies by Spinelli and Rosen (26) provided further
evidence against the age hypothesis. These investigators
could not demonstrate any in vitro age-related differences
in electrophysiologic effects of phenytoin on either normal
or depressed canine cardiac Purkinje fibers. Collectively,
these results suggest the importanceof the typeof underlying
heart disease in explaining the high therapeutic effectiveness
of type Ib antiarrhythmic agents in the "younger" age group.
Conclusions. Mexiletine is a useful agent for the long-
term control of ventricular arrhythmias in patients with con-
genital heart disease. Successful arrhythmia control is in-
dependent of arrhythmia complexity. For patients with ven-
triculararrhythmias occurring in the settingof cardiomyopathy
or no heart disease, mexiletine is not recommended. A high
concordance rate of therapeutic success makes mexiletine
an important alternative to phenytoin. Side effects are rel-
atively infrequent and mild in nature.
We acknowledge with gratitude the secretarial assistance of Terri Woods.
and thank Boehringer Ingelheim. Ltd. for supplying us with mexiletine.
References
I. Garson A. Randall DC, Gillette PC. et al. Prevention of sudden death
after repair of tetralogy of Fallot: treatment of ventricular arrhythmias.
J Am Coli Cardiol 1985;6:221-7.
2. Jewitt DE. Hemodynamic effects of newer antiarrhythmic drugs. Am
Heart J 1980;100:984-9.
J. Garson A. Gillette Pc. Treatment of chronic ventricular dysrhythmias
in the young. PACE 1981;4:658-69.
4. Kavey RE. Blackman MS. Sondheimer HM. Phenytoin therapy for
ventricular arrhythmias occurring late after surgery for congenital heart
disease. Am Heart J 1982;104:794-8.
5. Johansson BW. Stavenow L. Hanson A. Long-term clinical experience
with mexiletine. Am Heart J 1984:107:1099-102.
6. Rutledge JC. Harris F. Amsterdam EA. Skalsky E. Clinical evaluation
of oral mexiletine therapy in the treatment of ventricular arrhythmias.
J Am Coli Cardiol 1985;6:780-4
7. Flaker GC, Madigan NP. Alpert MA. Moser SA. Mexiletine for re-
curring ventricular arrhythmias: assessment by long-term electrocar-
diographic recordings and sequential electrophysiologic studies. Am
Heart J 1984:108490-5
8. Stein 1, Podrid PJ. Lampert S. Hirsowitz G. Lown B. Long term
mexiletine for ventricular arrhythmias. Am Heart J 1984:1 07:1091-8.
9. Woosley RL. Wang T. Slone W. et al. Pharmacology. electrophys-
iology and pharmacokinetics of mexiletine. Am Heart J 1984:107:
1058-65.
10. Hordof A. Steeg C. Davies M. Rosen MR. Variability of ventricular
ectopic frequency in children with chronic ventricular arrhythmias.
Circulation 198J;68(suppl 11I):J28.
II. Morganroth J. Michelson EL. Horowitz LN. Josephson ME. Pearlman
AS. Dunkman WB. Limitations of routine long term electrocardio-
graphic monitoring to assess ventricular ectopic frequency. Circulation
197858:408-14.
12. Wallenstein S. Zucker C. Fleiss JL. Some statistical methods useful
in circulation research. Circ Res 1980;47:1-9.
IJ. Garson A. Smith RT. Moak JP. Ross BA. McNamara DG. Ventricular
arrhythmias and sudden death in children. J Am Coli Cardiol 1985:6:
IJOB-JB.
14. Krongrad E. Hordof A1. Tachycardias in children. In: Surawicz B,
Reddy CPo Prystowsky EN. eds. Tachycardias. Boston: Martinus
Nijhoff. 19X4:319-54.
15. Cournel P, Fidelle 1. Arniodarone in the treatment of cardiac arrhyth-
mias in children: one hundred thirty-live cases. Am Heart J 19XO:100:
1063-9.
16. Garson A. Gillette PC McVey P. et al. Amiodarone treatment of
critical arrhythmias in children and young adults J Am Coil Cardiol
19X4:4:749-55.
17. Pickoff A, Singh S. Flinn C1. Wolff GS. Gelband H. Use of amio-
darone in the therapy of primary ventricular arrhythmias in children.
Dev Pharmacol Ther 19X3:6:7J-82.
18. Bergdahl DM. Stevenson JG. Kawabori 1, Guntheroth WG. Prognosis
of primary ventricular tachycardia in the pediatric patient. Circulation
1980:62:X97-901.
19. Smith DW. Recognizable Patterns of Human Malformation. Phila-
delphia: WB Saunders. 1982:414-7.
20. Garson A. Evaluation and treatment of chronic ventricular dysrhyth-
mias in the young. Cardiac Rev Rep 1981;2:1164-96.
21. Shanks RG. Hemodynamic effects of mexiletine. Am Heart J 1984:107:
1065-71
22. Ruskin IN. McGovern B. Garan H. DiMarco JP. Kelly E. Antiar-
rhythmic drugs: a possible cause of out of hospital cardiac arrest. N
Engl 1 Med 198J:J09:IJOI-8.
23. Velebit V. Podrid PJ. Lown B. Cohen BH. Grayboys TB. Aggravation
of ventricular arrhythmiasby antiarrhythmic drugs. Circulation 1982;65:
8X6-94.
24. Barton CWo Dick M. Rosenthal A. Quinidine syncope in children
(abxtr) J Am Coli Cardiel 19X5:5:429.
25. Garson A. Ventricular dysrhythmia» after congenital heart surgery: a
canine model. Pediatr Res 1984;18:1112-20.
26. Spinelli W. Rosen M. Developmental and use-dependent effects of
phenytoin in neonatal and adult Purkinje fibers (abstr). J Am Coil
CardioI1986;7:12JA.
